Table 3.

Commonly observed adverse events.

Adverse events (AEs)	Any grade, n (%)	Grade 3, n (%)	Grade 4, n (%)
Fatigue	30 (52.6)	5 (8.8)	0
Myelosuppression	21 (36.8)	6 (10.5)	1 (1.8)
Decreased appetite	19 (33.3)	4 (7.0)	0
Abdominal pain	15 (26.3)	3 (5.3)	0
ALT or AST elevation	12 (21.1)	4 (7.0)	0
Vomiting	11 (19.3)	2 (3.5)	0
Skin rash	11 (19.3)	3 (5.3)	0
Decreased weight	10 (17.5)	0	0
Hypertension	9 (15.8)	1 (1.8)	0
Hypothyroidism	8 (14.0)	1 (1.8)	0
Diarrhea	7 (12.3)	3 (5.3)	0
Proteinuria	6 (10.5)	0	0
Abdominal distention	4 (7.0)	0	0
Bilirubin elevation	4 (7.0)	1 (1.8)	1 (1.8)
Hand foot syndrome	4 (7.0)	0	0
Oral ulcer	3 (5.3)	0	0
Pneumonia	3 (5.3)	0	0
Gastrointestinal hemorrhage	2 (3.5)	1 (1.8)	0
Nasal hemorrhage	2 (3.5)	0	0
Myodynia	2 (3.5)	0	0
Constipation	1 (1.8)	0	0
Anemia	1 (1.8)	0	0
Decreased albumin	1 (1.8)	0	0

ALT, alanine aminotransferase; AST, aspartate aminotransferase.